Articulo
Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases
European Journal of Pharmaceutical Sciences
Autor
Giletti, Andrea
Vital, Marcelo
Lorenzo, Mariana
Cardozo, Patricia
Borelli, Gabriel
Gabus, Raúl
Martínez, Lem
Díaz, Lilian
Assar, Rodrigo
Rodríguez, María Noel
Esperón, Patricia
Institución
Resumen
BACKGROUND: Individual variability is among the causes of toxicity and interruption of treatment in acute lymphoblastic leukemia (ALL) and severe non-Hodgkin lymphoma (NHL) patients under protocols including Methotrexate (MTX): 2,4-diamino-N10-methyl prop FONDAP FONDAP